PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18698025-4 2008 In this study, we evaluated whether vandetanib (Zactima), a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinases, had antitumor efficacy in vitro and in an orthotopic nude mouse model of human ACC. vandetanib 36-46 epidermal growth factor receptor Mus musculus 128-132 21220477-10 2011 CONCLUSION: The inhibition of EGFR and VEGFR2 by vandetanib and its tremendous in vivo antitumor activity against ATC make it an attractive candidate for further preclinical and clinical development for the treatment of this particularly virulent cancer, which remains effectively untreatable. vandetanib 49-59 epidermal growth factor receptor Mus musculus 30-34 20629091-1 2011 BACKGROUND: We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carcinoma (HNSCC). vandetanib 43-53 epidermal growth factor receptor Mus musculus 119-123 20629091-4 2011 RESULTS: In vitro, vandetanib inhibited the phosphorylation of EGFR and its downstream targets in HNSCC cells and inhibited proliferation and induced apoptosis of HNSCC cells and extended survival and inhibited tumor growth in nude mice orthotopically injected with human HNSCC. vandetanib 19-29 epidermal growth factor receptor Mus musculus 63-67 22611027-2 2012 Vandetanib, a multikinase inhibitor, suppresses the phosphorylation of VEGF receptor 2 (VEGFR-2) and EGF receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Mus musculus 72-84 22611027-2 2012 Vandetanib, a multikinase inhibitor, suppresses the phosphorylation of VEGF receptor 2 (VEGFR-2) and EGF receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Mus musculus 89-93 22611027-8 2012 RESULTS: Vandetanib suppressed phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibited cell proliferation. vandetanib 9-19 epidermal growth factor receptor Mus musculus 51-55 22611027-9 2012 In tumor-bearing mice, vandetanib suppressed phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduced tumor vessel density, enhanced tumor cell apoptosis, suppressed tumor growth, improved survival, reduced number of intrahepatic metastases, and upregulated VEGF, TGF-alpha, and EGF in tumor tissues. vandetanib 23-33 epidermal growth factor receptor Mus musculus 65-69 18698025-5 2008 EXPERIMENTAL DESIGN: The in vitro effects of vandetanib were assessed in three ACC cell lines on cell growth, apoptosis, and VEGFR-2 and EGFR phosphorylation levels. vandetanib 45-55 epidermal growth factor receptor Mus musculus 126-130 18698025-9 2008 RESULTS: In vitro, vandetanib caused dose-dependent inhibition of VEGFR-2 and EGFR phosphorylation in ACC cells. vandetanib 19-29 epidermal growth factor receptor Mus musculus 67-71 17639056-7 2007 Treatment of tumor-bearing nude mice with the tyrosine kinase inhibitor ZD6474, which specifically inhibits RET, epidermal growth factor receptor (EGFR), and vascular endothelium growth factor receptor (VEGFR) tyrosine kinases, resulted in a dose-dependent inhibition of tumor growth. vandetanib 72-78 epidermal growth factor receptor Mus musculus 113-145 18347145-4 2008 In this study, we have assessed the effect of inhibiting both these key pathways simultaneously using ZD6474 (Vandetanib, ZACTIMA), a selective inhibitor of VEGFR and EGFR tyrosine kinases. vandetanib 102-108 epidermal growth factor receptor Mus musculus 158-162 18347145-4 2008 In this study, we have assessed the effect of inhibiting both these key pathways simultaneously using ZD6474 (Vandetanib, ZACTIMA), a selective inhibitor of VEGFR and EGFR tyrosine kinases. vandetanib 110-120 epidermal growth factor receptor Mus musculus 158-162 17975157-1 2007 PURPOSE: This in vivo study was designed to determine the optimal doses and schedules of vandetanib, a dual epidermal growth factor receptor (EGFR)-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan in a murine xenograft model of human colon cancer. vandetanib 89-99 epidermal growth factor receptor Mus musculus 108-140 17975157-1 2007 PURPOSE: This in vivo study was designed to determine the optimal doses and schedules of vandetanib, a dual epidermal growth factor receptor (EGFR)-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan in a murine xenograft model of human colon cancer. vandetanib 89-99 epidermal growth factor receptor Mus musculus 142-146 17639056-7 2007 Treatment of tumor-bearing nude mice with the tyrosine kinase inhibitor ZD6474, which specifically inhibits RET, epidermal growth factor receptor (EGFR), and vascular endothelium growth factor receptor (VEGFR) tyrosine kinases, resulted in a dose-dependent inhibition of tumor growth. vandetanib 72-78 epidermal growth factor receptor Mus musculus 147-151 16052530-2 2006 To investigate their therapeutic potential, we examined the effect of ZD6474, an agent that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2; KDR) tyrosine kinase and epidermal growth factor receptor (EGFR) tyrosine kinase, in a highly metastatic orthotopic model using an undifferentiated gastric cancer cell line, 58As1. vandetanib 70-76 epidermal growth factor receptor Mus musculus 160-164 16299247-0 2005 ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. vandetanib 0-6 epidermal growth factor receptor Mus musculus 93-125 16299247-4 2005 EXPERIMENTAL DESIGN: ZD6474 is a novel, orally available low molecular weight inhibitor of the kinase activities associated with vascular endothelial growth factor receptor-2 and epidermal growth factor receptor. vandetanib 21-27 epidermal growth factor receptor Mus musculus 179-211 15886878-2 2004 ZD6474 is a novel inhibitor of VEGF receptor-2 (VEGFR-2) tyrosine kinase activity, which also has additional activity against epidermal growth factor (EGF) receptor tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Mus musculus 126-164 14760102-23 2004 Growth of EGFR inhibitor-resistant tumors can be inhibited by ZD6474. vandetanib 62-68 epidermal growth factor receptor Mus musculus 10-14 12684431-7 2003 RESULTS: ZD6474 causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. vandetanib 9-15 epidermal growth factor receptor Mus musculus 54-58 12684431-7 2003 RESULTS: ZD6474 causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. vandetanib 9-15 epidermal growth factor receptor Mus musculus 88-92 12684431-10 2003 ZD6474 treatment of nude mice bearing palpable GEO colon cancer xenografts (which are sensitive to inhibition of EGFR signaling) induced dose-dependent tumor growth inhibition. vandetanib 0-6 epidermal growth factor receptor Mus musculus 113-117 27549668-0 2016 Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. vandetanib 10-20 epidermal growth factor receptor Mus musculus 85-89 27549668-1 2016 Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-10 epidermal growth factor receptor Mus musculus 130-162 27549668-1 2016 Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-10 epidermal growth factor receptor Mus musculus 118-122 27549668-4 2016 In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. vandetanib 25-35 epidermal growth factor receptor Mus musculus 108-112 27549668-7 2016 These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation. vandetanib 24-34 epidermal growth factor receptor Mus musculus 100-104